Form D · Biotechnology
BOREAL GENOMICS INC.
Vancouver, A1 · CIK 0001505963
Offering snapshot reported Oct 11, 2013 · SEC filing
- Reported sold
- $18M Offering amount: $18M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 30, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 11, 2013 | Initial | $17,999,997 | No comparison | 5 | SEC filing |
| Dec 16, 2010 | Initial | $6,499,999 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-204450
Source: Form D, filed Oct 11, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Broemeling | Executive |
| David Broemling | Executive |
| Caley Castelein | Director |
| Keith Crandall | Director |
| Keith Crandell | Director |
| Andrea Marziali | Director, Executive |
| Andre Marziali | Director, Executive |
| Nicholas Naclerio | Director |
| Nitin Sood | Director, Executive |
| Thomas Willis | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2386 East Mall.
Vancouver, A1, V6T1Z3
Vancouver, A1, V6T1Z3